Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00362037
Status:
COMPLETED
Last Update Posted:
2011-05-30
First Post:
2006-08-08
Brief Title:
I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate Blood Pressure BP reduction to the targeted values BP 14090 mm Hg in non-diabetic patients and 13080 mm Hg in diabetic patients
To emphasize and to evaluate the benefit of Irbesartan in the reduction of left ventricular mass index in hypertensive patients with left ventricular hypertrophy
To demonstrate safety of Irbesartan in this population
To emphasize and to evaluate the benefit of Irbesartan in the reduction of left ventricular mass index in hypertensive patients with left ventricular hypertrophy
To demonstrate safety of Irbesartan in this population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None